Similarly, in relapsed platinum-sensitive high-grade ovarian cancer patients, therapeutic responses to Rucaparib were not restricted to BRCA-mutated tumors, and were observed in several patients with mutations to other HR genes including ATM, NBN, RAD51C, and RAD51D [132]. The gene discussed is RAD51D; the disease is ovarian carcinoma.